Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. AHR is a Zika virus host factor and a candidate target for antiviral therapy

AHR is a Zika virus host factor and a candidate target for antiviral therapy

Thumbnail Image
Download
Name

nihms-1668695.pdf

Description
Accepted version
Size

4.21 MB

Format

Unknown

Checksum (MD5)

d5ffe99423806f229cfdf616c4b46f40

sword-2021-12-08T19:21:56.original.xml (130 B)
Original SWORD entry document
Author(s)
Giovannoni, Federico
•
Bosch, Irene
•
Polonio, Carolina Manganeli
•
Torti, María F.
•
Wheeler, Michael A.
•
Li, Zhaorong
•
Romorini, Leonardo
•
Rodriguez Varela, María S.
•
Rothhammer, Veit
•
Barroso, Andreia
more
Date Issued
July 2020
Journal
Nature Neuroscience
Publisher
Springer Science and Business Media LLC
Citation
Giovannoni, Federico, Bosch, Irene, Polonio, Carolina Manganeli, Torti, María F, Wheeler, Michael A et al. 2020. "AHR is a Zika virus host factor and a candidate target for antiviral therapy." Nature Neuroscience, 23 (8).
Version
Author's final manuscript
Abstract
Zika virus (ZIKV) is a flavivirus linked to multiple birth defects including microcephaly, known as congenital ZIKV syndrome. The identification of host factors involved in ZIKV replication may guide efficacious therapeutic interventions. In genome-wide transcriptional studies, we found that ZIKV infection triggers aryl hydrocarbon receptor (AHR) activation. Specifically, ZIKV infection induces kynurenine (Kyn) production, which activates AHR, limiting the production of type I interferons (IFN-I) involved in antiviral immunity. Moreover, ZIKV-triggered AHR activation suppresses intrinsic immunity driven by the promyelocytic leukemia (PML) protein, which limits ZIKV replication. AHR inhibition suppressed the replication of multiple ZIKV strains in vitro and also suppressed replication of the related flavivirus dengue. Finally, AHR inhibition with a nanoparticle-delivered AHR antagonist or an inhibitor developed for human use limited ZIKV replication and ameliorated newborn microcephaly in a murine model. In summary, we identified AHR as a host factor for ZIKV replication and PML protein as a driver of anti-ZIKV intrinsic immunity.
MIT Department
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
https://hdl.handle.net/1721.1/138398.2
DOI of Published Version
https://doi.org/10.1038/s41593-020-0664-0
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.